After a nine-year run, AbbVie is calling it quits on its Reata Pharmaceuticals partnership. The Big Pharma, which ponied up more than $800 million for the rights to a set of Nrf2 activators for kidney disease and autoimmune disease, is now handing those rights back for $330 million in cash.